# Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning

> **NCT02470910** · NA · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 15 (actual)

## Conditions studied

- Prostate Cancer
- Adenocarcinoma of the Prostate Stage I
- Adenocarcinoma of the Prostate Stage II
- Adenocarcinoma of the Prostate Stage III

## Interventions

- **DEVICE:** Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT02470910
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2018-07
- **Final completion:** 2018-07
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2019-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02470910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02470910, "Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02470910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*